Pheno is focused on the discovery and development of small molecule therapeutics that promote remyelination. It is a phenomenon in which new myelin sheaths are generated around axons in the adult central nervous system, especially in diseases such as multiple sclerosis.
The agreement with UCB grants Pheno access and rights to develop, manufacture and commercialize a preclinical stage program of novel small molecules designed to promote remyelination.
Fraser Murray, CEO of Pheno, said: “We have utilized our proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets for modulating oligodendrocyte biology and promoting remyelination. can accelerate clinical development of new drug targets.na
“Combined with our human neuropharmaceutical development expertise, Pheno Therapeutics will accelerate this program towards clinical proof-of-concept studies, potentially providing innovative drugs for the treatment of demyelinating diseases. We have a big opportunity.”na
Pheno will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialization. UCB will receive milestones and tiered royalties on net sales. Financial details of the deal were not disclosed.
“Such a licensing agreement is a demonstration of the value that UCB scientists and their partners are creating through strong research productivity, where Pheno Therapeutics, with its expertise in phenotypic screening, stem cell technology, and myelin biology, Develop this preclinical program to reach its full potentialsaid Dhaval Patel, Executive Vice President and Chief Scientific Officer of UCB.
Pheno Therapeutics will make a one-time upfront payment and will be responsible for development, manufacturing and global commercialization. UCB will receive milestones and tiered royalties on net sales. Financial details of the deal were not disclosed.
The preclinical program seems to selectively modulate the activity of undisclosed targets that are preferentially expressed in human oligodendrocytes and known to play important roles in biological pathways and myelination processes. Designed to
Multiple sclerosis can affect both the brain and spinal cord, and can cause symptoms such as loss of sensation or balance, visual disturbances, and movement in the arms and legs. However, it is a lifelong condition that can lead to severe disability.
Existing treatments include short courses of steroids to hasten recovery and delay or reduce overall deterioration in patients with relapsing or relapsing MS and in patients with relapsed primary and secondary progressive MS. Includes disease-modifying therapies that help
